FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3107797672> ?p ?o ?g. }

• W3107797672 endingPage "102641" @default.
• W3107797672 startingPage "102641" @default.
• W3107797672 abstract "BackgroundAntibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in astrocyte damage and subsequent neuronal injury. The PREVENT study demonstrated that the terminal complement inhibitor eculizumab reduces adjudicated relapse risk in patients with anti-AQP4 immunoglobulin G-positive (AQP4+) NMOSD. The objective of this analysis was to evaluate the efficacy of eculizumab in reducing relapse risk and its safety in AQP4+ NMOSD across clinically relevant subgroups in PREVENT.MethodsIn the randomized, double-blind, time-to-event, phase 3 PREVENT trial, 143 adults received eculizumab (maintenance dose, 1200 mg/2 weeks) or placebo (2:1), with stable-dose concomitant immunosuppressive therapy (IST) permitted (except rituximab and mitoxantrone). Post hoc analyses of relapses and adverse events were performed for prespecified and post hoc subgroups based on concomitant IST and prior rituximab use, demographic and disease characteristics, and autoimmune comorbidity.ResultsThe significant reduction in relapse risk observed for eculizumab versus placebo in the overall PREVENT population was consistently maintained across subgroups based on concomitant IST and previous rituximab use, age, sex, region, race, time since clinical onset of NMOSD, historical annualized relapse rate, baseline Expanded Disability Status Scale score, and history of another autoimmune disorder. The serious infection rate was lower with eculizumab than placebo regardless of rituximab use in the previous year, concomitant IST use, or history of another autoimmune disorder.ConclusionAcross a wide range of clinically relevant AQP4+ NMOSD patient subgroups in PREVENT, eculizumab therapy was consistently effective versus placebo in reducing relapse risk, with no apparent increase in serious infection rate.Trial registrationNCT01892345 (ClinicalTrials.gov)." @default.
• W3107797672 created "2020-12-07" @default.
• W3107797672 creator A5002850283 @default.
• W3107797672 creator A5006100482 @default.
• W3107797672 creator A5008002660 @default.
• W3107797672 creator A5009021406 @default.
• W3107797672 creator A5009161348 @default.
• W3107797672 creator A5018300417 @default.
• W3107797672 creator A5020356606 @default.
• W3107797672 creator A5027362230 @default.
• W3107797672 creator A5028669492 @default.
• W3107797672 creator A5037467867 @default.
• W3107797672 creator A5055386778 @default.
• W3107797672 creator A5066417034 @default.
• W3107797672 creator A5068037677 @default.
• W3107797672 creator A5072650322 @default.
• W3107797672 creator A5077929630 @default.
• W3107797672 creator A5088136783 @default.
• W3107797672 creator A5088301395 @default.
• W3107797672 date "2021-01-01" @default.
• W3107797672 modified "2023-10-15" @default.
• W3107797672 title "Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial" @default.
• W3107797672 cites W1823172479 @default.
• W3107797672 cites W2007556864 @default.
• W3107797672 cites W2021279859 @default.
• W3107797672 cites W2029012161 @default.
• W3107797672 cites W2046068958 @default.
• W3107797672 cites W2053472907 @default.
• W3107797672 cites W2087529564 @default.
• W3107797672 cites W2092102896 @default.
• W3107797672 cites W2107941546 @default.
• W3107797672 cites W2156918730 @default.
• W3107797672 cites W2342633119 @default.
• W3107797672 cites W2524675862 @default.
• W3107797672 cites W2747029006 @default.
• W3107797672 cites W2754643113 @default.
• W3107797672 cites W2766784006 @default.
• W3107797672 cites W2886993422 @default.
• W3107797672 cites W2896045114 @default.
• W3107797672 cites W2901083534 @default.
• W3107797672 cites W2914587352 @default.
• W3107797672 cites W2921308094 @default.
• W3107797672 cites W2924444286 @default.
• W3107797672 cites W2932668297 @default.
• W3107797672 cites W2943416206 @default.
• W3107797672 cites W3012054652 @default.
• W3107797672 cites W3012376934 @default.
• W3107797672 doi "https://doi.org/10.1016/j.msard.2020.102641" @default.
• W3107797672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33310418" @default.
• W3107797672 hasPublicationYear "2021" @default.
• W3107797672 type Work @default.
• W3107797672 sameAs 3107797672 @default.
• W3107797672 citedByCount "23" @default.
• W3107797672 countsByYear W31077976722021 @default.
• W3107797672 countsByYear W31077976722022 @default.
• W3107797672 countsByYear W31077976722023 @default.
• W3107797672 crossrefType "journal-article" @default.
• W3107797672 hasAuthorship W3107797672A5002850283 @default.
• W3107797672 hasAuthorship W3107797672A5006100482 @default.
• W3107797672 hasAuthorship W3107797672A5008002660 @default.
• W3107797672 hasAuthorship W3107797672A5009021406 @default.
• W3107797672 hasAuthorship W3107797672A5009161348 @default.
• W3107797672 hasAuthorship W3107797672A5018300417 @default.
• W3107797672 hasAuthorship W3107797672A5020356606 @default.
• W3107797672 hasAuthorship W3107797672A5027362230 @default.
• W3107797672 hasAuthorship W3107797672A5028669492 @default.
• W3107797672 hasAuthorship W3107797672A5037467867 @default.
• W3107797672 hasAuthorship W3107797672A5055386778 @default.
• W3107797672 hasAuthorship W3107797672A5066417034 @default.
• W3107797672 hasAuthorship W3107797672A5068037677 @default.
• W3107797672 hasAuthorship W3107797672A5072650322 @default.
• W3107797672 hasAuthorship W3107797672A5077929630 @default.
• W3107797672 hasAuthorship W3107797672A5088136783 @default.
• W3107797672 hasAuthorship W3107797672A5088301395 @default.
• W3107797672 hasBestOaLocation W31077976721 @default.
• W3107797672 hasConcept C111684460 @default.
• W3107797672 hasConcept C126322002 @default.
• W3107797672 hasConcept C142724271 @default.
• W3107797672 hasConcept C159654299 @default.
• W3107797672 hasConcept C197934379 @default.
• W3107797672 hasConcept C203014093 @default.
• W3107797672 hasConcept C204787440 @default.
• W3107797672 hasConcept C27081682 @default.
• W3107797672 hasConcept C2777991916 @default.
• W3107797672 hasConcept C2779338263 @default.
• W3107797672 hasConcept C2779384505 @default.
• W3107797672 hasConcept C2780640218 @default.
• W3107797672 hasConcept C2780653079 @default.
• W3107797672 hasConcept C2781137167 @default.
• W3107797672 hasConcept C2908647359 @default.
• W3107797672 hasConcept C71924100 @default.
• W3107797672 hasConcept C99454951 @default.
• W3107797672 hasConceptScore W3107797672C111684460 @default.
• W3107797672 hasConceptScore W3107797672C126322002 @default.
• W3107797672 hasConceptScore W3107797672C142724271 @default.
• W3107797672 hasConceptScore W3107797672C159654299 @default.
• W3107797672 hasConceptScore W3107797672C197934379 @default.
• W3107797672 hasConceptScore W3107797672C203014093 @default.

• next